世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の個別化がん医療市場の成長(現状と展望)2023-2029年


Global Personalized Cancer Medicine Market Growth (Status and Outlook) 2023-2029

LPI(LPインフォメーション)の最新調査によると、個別化がん治療薬の世界市場規模は2022年に1581億8000万米ドルとなった。下流市場での需要拡大に伴い、個別化がん治療薬は2029年までに371130万米ドルの再調整規... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年10月8日 US$3,660
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
124 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、個別化がん治療薬の世界市場規模は2022年に1581億8000万米ドルとなった。下流市場での需要拡大に伴い、個別化がん治療薬は2029年までに371130万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは13.0%である。
この調査レポートは、世界の個別化がん治療薬市場の成長可能性を明らかにしている。個別化がん治療薬は、今後の市場において安定した成長を示すと予想される。しかし、個別化がん治療薬の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場参入企業は、研究開発への投資、戦略的パートナーシップの構築、進化する消費者の嗜好に合わせた製品提供など、個別化がん医療市場がもたらす莫大な機会を活用する必要がある。
個別化がん医療は、標的治療薬や精密医薬品としても知られ、個々の患者のがんに特有の遺伝的・分子的特徴を特異的に標的とするように設計された医薬品である。これらの薬剤は個別化がん医療の中心的な要素であり、患者の腫瘍のゲノムおよび分子プロファイリングに基づいて選択される。
免疫療法:伝統的な標的療法ではないが、免疫チェックポイント阻害剤のような免疫療法も個別化がん治療の一つである。これらの薬剤は、がん細胞を認識し攻撃するために患者の免疫系を強化し、腫瘍の分子的特徴に基づいて患者に合わせることができる。
個別化がん治療薬は、がん専門医が各患者のがんの特徴に合わせて治療計画を立てることを可能にし、がん治療に革命をもたらした。このアプローチは、予後を改善し、従来のがん治療に伴う副作用を軽減する上で大きな期待が寄せられている。しかし、標的療法のレパートリーを拡大し、より多くのがん患者が利用できるようにするためには、継続的な研究と進歩が必要である。
世界市場において、精密がん医療(個別化がん医療)の中心的メーカーは、アッヴィ、ジョンソン・エンド・ジョンソン、ノバルティスなどである。この業界では上位3社が市場シェアの約30%を占めている。北米、欧州、アジア太平洋地域がこの製品の主要製造地域で、北米が世界市場シェアの50%以上を占めている。同製品は、治療法によって免疫療法薬と標的治療薬に分類される。同製品は、肺がん、乳がん、前立腺がん、血液がんなどの治療に広く使用されている。
主な特徴
個別化がん治療薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、個別化がん治療薬市場の現在の規模と成長の概要を提供します。過去データ、方法別市場細分化(がん免疫療法、標的療法など)、地域別細分化などが含まれます。
市場促進要因と課題:政府規制、環境問題、技術進歩、消費者嗜好の変化など、個別化がん治療薬市場の成長を促進する要因を特定・分析することができる。また、インフラストラクチャーの制約、射程距離への不安、初期コストの高さなど、業界が直面する課題も浮き彫りにすることができる。
競合情勢:この調査レポートは、個別化がん医療市場における競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその市場に与える潜在的な影響にもスポットを当てることができる。
技術開発:この調査レポートは、個別化がん治療薬業界における最新の技術開発を掘り下げることができます。これには、個別化がん治療薬技術の進歩、個別化がん治療薬の新規参入、個別化がん治療薬の新規投資、個別化がん治療薬の将来を形作るその他の技術革新が含まれる。
川下の事業者の好み:本レポートは、個別化がん医療市場における顧客の購買行動と採用動向を明らかにすることができる。このレポートには、顧客の購買決定、個別化がん医療製品の嗜好に影響を与える要因が含まれている。
政府の政策とインセンティブこの調査レポートは、政府の政策やインセンティブが個別化がん医療市場に与える影響を分析している。これには、規制の枠組み、補助金、税制優遇措置、その他個別化がん医療市場の促進を目的とした施策の評価が含まれる。また、市場成長促進におけるこれらの政策の有効性も評価する。
環境への影響と持続可能性この調査レポートは、個別化がん医療市場の環境への影響と持続可能性の側面を評価しています。
市場予測と将来展望:実施した分析に基づき、調査レポートは個別化がん治療薬産業の市場予測と展望を提供する。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれる。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられている。市場関係者が新たなトレンドを活用し、課題を克服し、個別化がん医療市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場細分化:
個別化がん医療市場は、方法別と用途別に分割される。2018年から2029年までの期間について、セグメント間の成長により、方法別、用途別の消費額の正確な計算と予測を提供します。
方法別セグメント
がん免疫療法
標的療法
用途別セグメント
肺がん
乳がん
前立腺がん
血液関連癌
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
アッヴィ
ジョンソン・エンド・ジョンソン
ノバルティス
ギリアド・サイエンシズ
ロシュ
ブリストル・マイヤーズ スクイブ
アムジェン
アストラゼネカ
メルク・アンド・カンパニー
武田薬品工業
メルクKGaA
セーゲン
イーライリリー
小野薬品工業
ファイザー
ジーエスケー
エクセリクシス
リジェネロン
イノベント
恒瑞医薬


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Personalized Cancer Medicine Market Size 2018-2029
2.1.2 Personalized Cancer Medicine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Personalized Cancer Medicine Segment by Method
2.2.1 Cancer Immunotherapy
2.2.2 Targeted Therapy
2.3 Personalized Cancer Medicine Market Size by Method
2.3.1 Personalized Cancer Medicine Market Size CAGR by Method (2018 VS 2022 VS 2029)
2.3.2 Global Personalized Cancer Medicine Market Size Market Share by Method (2018-2023)
2.4 Personalized Cancer Medicine Segment by Application
2.4.1 Lung Cancer
2.4.2 Breast Cancer
2.4.3 Prostate Cancer
2.4.4 Blood-related Cancer
2.4.5 Other
2.5 Personalized Cancer Medicine Market Size by Application
2.5.1 Personalized Cancer Medicine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Personalized Cancer Medicine Market Size Market Share by Application (2018-2023)
3 Personalized Cancer Medicine Market Size by Player
3.1 Personalized Cancer Medicine Market Size Market Share by Players
3.1.1 Global Personalized Cancer Medicine Revenue by Players (2018-2023)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Personalized Cancer Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Personalized Cancer Medicine by Regions
4.1 Personalized Cancer Medicine Market Size by Regions (2018-2023)
4.2 Americas Personalized Cancer Medicine Market Size Growth (2018-2023)
4.3 APAC Personalized Cancer Medicine Market Size Growth (2018-2023)
4.4 Europe Personalized Cancer Medicine Market Size Growth (2018-2023)
4.5 Middle East & Africa Personalized Cancer Medicine Market Size Growth (2018-2023)
5 Americas
5.1 Americas Personalized Cancer Medicine Market Size by Country (2018-2023)
5.2 Americas Personalized Cancer Medicine Market Size by Method (2018-2023)
5.3 Americas Personalized Cancer Medicine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Personalized Cancer Medicine Market Size by Region (2018-2023)
6.2 APAC Personalized Cancer Medicine Market Size by Method (2018-2023)
6.3 APAC Personalized Cancer Medicine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Personalized Cancer Medicine by Country (2018-2023)
7.2 Europe Personalized Cancer Medicine Market Size by Method (2018-2023)
7.3 Europe Personalized Cancer Medicine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Personalized Cancer Medicine by Region (2018-2023)
8.2 Middle East & Africa Personalized Cancer Medicine Market Size by Method (2018-2023)
8.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Personalized Cancer Medicine Market Forecast
10.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029)
10.1.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029)
10.1.2 Americas Personalized Cancer Medicine Forecast
10.1.3 APAC Personalized Cancer Medicine Forecast
10.1.4 Europe Personalized Cancer Medicine Forecast
10.1.5 Middle East & Africa Personalized Cancer Medicine Forecast
10.2 Americas Personalized Cancer Medicine Forecast by Country (2024-2029)
10.2.1 United States Personalized Cancer Medicine Market Forecast
10.2.2 Canada Personalized Cancer Medicine Market Forecast
10.2.3 Mexico Personalized Cancer Medicine Market Forecast
10.2.4 Brazil Personalized Cancer Medicine Market Forecast
10.3 APAC Personalized Cancer Medicine Forecast by Region (2024-2029)
10.3.1 China Personalized Cancer Medicine Market Forecast
10.3.2 Japan Personalized Cancer Medicine Market Forecast
10.3.3 Korea Personalized Cancer Medicine Market Forecast
10.3.4 Southeast Asia Personalized Cancer Medicine Market Forecast
10.3.5 India Personalized Cancer Medicine Market Forecast
10.3.6 Australia Personalized Cancer Medicine Market Forecast
10.4 Europe Personalized Cancer Medicine Forecast by Country (2024-2029)
10.4.1 Germany Personalized Cancer Medicine Market Forecast
10.4.2 France Personalized Cancer Medicine Market Forecast
10.4.3 UK Personalized Cancer Medicine Market Forecast
10.4.4 Italy Personalized Cancer Medicine Market Forecast
10.4.5 Russia Personalized Cancer Medicine Market Forecast
10.5 Middle East & Africa Personalized Cancer Medicine Forecast by Region (2024-2029)
10.5.1 Egypt Personalized Cancer Medicine Market Forecast
10.5.2 South Africa Personalized Cancer Medicine Market Forecast
10.5.3 Israel Personalized Cancer Medicine Market Forecast
10.5.4 Turkey Personalized Cancer Medicine Market Forecast
10.5.5 GCC Countries Personalized Cancer Medicine Market Forecast
10.6 Global Personalized Cancer Medicine Forecast by Method (2024-2029)
10.7 Global Personalized Cancer Medicine Forecast by Application (2024-2029)

11 Key Players Analysis
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Personalized Cancer Medicine Product Offered
11.1.3 AbbVie Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Personalized Cancer Medicine Product Offered
11.2.3 Johnson & Johnson Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Personalized Cancer Medicine Product Offered
11.3.3 Novartis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Information
11.4.2 Gilead Sciences Personalized Cancer Medicine Product Offered
11.4.3 Gilead Sciences Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Gilead Sciences Main Business Overview
11.4.5 Gilead Sciences Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Personalized Cancer Medicine Product Offered
11.5.3 Roche Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Personalized Cancer Medicine Product Offered
11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Personalized Cancer Medicine Product Offered
11.7.3 Amgen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Amgen Main Business Overview
11.7.5 Amgen Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Personalized Cancer Medicine Product Offered
11.8.3 AstraZeneca Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Merck & Co
11.9.1 Merck & Co Company Information
11.9.2 Merck & Co Personalized Cancer Medicine Product Offered
11.9.3 Merck & Co Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Merck & Co Main Business Overview
11.9.5 Merck & Co Latest Developments
11.10 Takeda
11.10.1 Takeda Company Information
11.10.2 Takeda Personalized Cancer Medicine Product Offered
11.10.3 Takeda Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Takeda Main Business Overview
11.10.5 Takeda Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Personalized Cancer Medicine Product Offered
11.11.3 Merck KGaA Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Seagen
11.12.1 Seagen Company Information
11.12.2 Seagen Personalized Cancer Medicine Product Offered
11.12.3 Seagen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Seagen Main Business Overview
11.12.5 Seagen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Personalized Cancer Medicine Product Offered
11.13.3 Eli Lilly Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Information
11.14.2 Ono Pharmaceutical Personalized Cancer Medicine Product Offered
11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Ono Pharmaceutical Main Business Overview
11.14.5 Ono Pharmaceutical Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Personalized Cancer Medicine Product Offered
11.15.3 Pfizer Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 GSK
11.16.1 GSK Company Information
11.16.2 GSK Personalized Cancer Medicine Product Offered
11.16.3 GSK Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 GSK Main Business Overview
11.16.5 GSK Latest Developments
11.17 Exelixis
11.17.1 Exelixis Company Information
11.17.2 Exelixis Personalized Cancer Medicine Product Offered
11.17.3 Exelixis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Exelixis Main Business Overview
11.17.5 Exelixis Latest Developments
11.18 Regeneron
11.18.1 Regeneron Company Information
11.18.2 Regeneron Personalized Cancer Medicine Product Offered
11.18.3 Regeneron Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Regeneron Main Business Overview
11.18.5 Regeneron Latest Developments
11.19 Innovent
11.19.1 Innovent Company Information
11.19.2 Innovent Personalized Cancer Medicine Product Offered
11.19.3 Innovent Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Innovent Main Business Overview
11.19.5 Innovent Latest Developments
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Information
11.20.2 Hengrui Medicine Personalized Cancer Medicine Product Offered
11.20.3 Hengrui Medicine Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Hengrui Medicine Main Business Overview
11.20.5 Hengrui Medicine Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Personalized Cancer Medicine market size was valued at US$ 158180 million in 2022. With growing demand in downstream market, the Personalized Cancer Medicine is forecast to a readjusted size of US$ 371130 million by 2029 with a CAGR of 13.0% during review period.
The research report highlights the growth potential of the global Personalized Cancer Medicine market. Personalized Cancer Medicine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Personalized Cancer Medicine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Personalized Cancer Medicine market.
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
Key Features:
The report on Personalized Cancer Medicine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Personalized Cancer Medicine market. It may include historical data, market segmentation by Method (e.g., Cancer Immunotherapy, Targeted Therapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Personalized Cancer Medicine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Personalized Cancer Medicine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Personalized Cancer Medicine industry. This include advancements in Personalized Cancer Medicine technology, Personalized Cancer Medicine new entrants, Personalized Cancer Medicine new investment, and other innovations that are shaping the future of Personalized Cancer Medicine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Personalized Cancer Medicine market. It includes factors influencing customer ' purchasing decisions, preferences for Personalized Cancer Medicine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Personalized Cancer Medicine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Personalized Cancer Medicine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Personalized Cancer Medicine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Personalized Cancer Medicine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Personalized Cancer Medicine market.
Market Segmentation:
Personalized Cancer Medicine market is split by Method and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Method, and by Application in terms of value.
Segmentation by method
Cancer Immunotherapy
Targeted Therapy
Segmentation by application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Personalized Cancer Medicine Market Size 2018-2029
2.1.2 Personalized Cancer Medicine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Personalized Cancer Medicine Segment by Method
2.2.1 Cancer Immunotherapy
2.2.2 Targeted Therapy
2.3 Personalized Cancer Medicine Market Size by Method
2.3.1 Personalized Cancer Medicine Market Size CAGR by Method (2018 VS 2022 VS 2029)
2.3.2 Global Personalized Cancer Medicine Market Size Market Share by Method (2018-2023)
2.4 Personalized Cancer Medicine Segment by Application
2.4.1 Lung Cancer
2.4.2 Breast Cancer
2.4.3 Prostate Cancer
2.4.4 Blood-related Cancer
2.4.5 Other
2.5 Personalized Cancer Medicine Market Size by Application
2.5.1 Personalized Cancer Medicine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Personalized Cancer Medicine Market Size Market Share by Application (2018-2023)
3 Personalized Cancer Medicine Market Size by Player
3.1 Personalized Cancer Medicine Market Size Market Share by Players
3.1.1 Global Personalized Cancer Medicine Revenue by Players (2018-2023)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Personalized Cancer Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Personalized Cancer Medicine by Regions
4.1 Personalized Cancer Medicine Market Size by Regions (2018-2023)
4.2 Americas Personalized Cancer Medicine Market Size Growth (2018-2023)
4.3 APAC Personalized Cancer Medicine Market Size Growth (2018-2023)
4.4 Europe Personalized Cancer Medicine Market Size Growth (2018-2023)
4.5 Middle East & Africa Personalized Cancer Medicine Market Size Growth (2018-2023)
5 Americas
5.1 Americas Personalized Cancer Medicine Market Size by Country (2018-2023)
5.2 Americas Personalized Cancer Medicine Market Size by Method (2018-2023)
5.3 Americas Personalized Cancer Medicine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Personalized Cancer Medicine Market Size by Region (2018-2023)
6.2 APAC Personalized Cancer Medicine Market Size by Method (2018-2023)
6.3 APAC Personalized Cancer Medicine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Personalized Cancer Medicine by Country (2018-2023)
7.2 Europe Personalized Cancer Medicine Market Size by Method (2018-2023)
7.3 Europe Personalized Cancer Medicine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Personalized Cancer Medicine by Region (2018-2023)
8.2 Middle East & Africa Personalized Cancer Medicine Market Size by Method (2018-2023)
8.3 Middle East & Africa Personalized Cancer Medicine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Personalized Cancer Medicine Market Forecast
10.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029)
10.1.1 Global Personalized Cancer Medicine Forecast by Regions (2024-2029)
10.1.2 Americas Personalized Cancer Medicine Forecast
10.1.3 APAC Personalized Cancer Medicine Forecast
10.1.4 Europe Personalized Cancer Medicine Forecast
10.1.5 Middle East & Africa Personalized Cancer Medicine Forecast
10.2 Americas Personalized Cancer Medicine Forecast by Country (2024-2029)
10.2.1 United States Personalized Cancer Medicine Market Forecast
10.2.2 Canada Personalized Cancer Medicine Market Forecast
10.2.3 Mexico Personalized Cancer Medicine Market Forecast
10.2.4 Brazil Personalized Cancer Medicine Market Forecast
10.3 APAC Personalized Cancer Medicine Forecast by Region (2024-2029)
10.3.1 China Personalized Cancer Medicine Market Forecast
10.3.2 Japan Personalized Cancer Medicine Market Forecast
10.3.3 Korea Personalized Cancer Medicine Market Forecast
10.3.4 Southeast Asia Personalized Cancer Medicine Market Forecast
10.3.5 India Personalized Cancer Medicine Market Forecast
10.3.6 Australia Personalized Cancer Medicine Market Forecast
10.4 Europe Personalized Cancer Medicine Forecast by Country (2024-2029)
10.4.1 Germany Personalized Cancer Medicine Market Forecast
10.4.2 France Personalized Cancer Medicine Market Forecast
10.4.3 UK Personalized Cancer Medicine Market Forecast
10.4.4 Italy Personalized Cancer Medicine Market Forecast
10.4.5 Russia Personalized Cancer Medicine Market Forecast
10.5 Middle East & Africa Personalized Cancer Medicine Forecast by Region (2024-2029)
10.5.1 Egypt Personalized Cancer Medicine Market Forecast
10.5.2 South Africa Personalized Cancer Medicine Market Forecast
10.5.3 Israel Personalized Cancer Medicine Market Forecast
10.5.4 Turkey Personalized Cancer Medicine Market Forecast
10.5.5 GCC Countries Personalized Cancer Medicine Market Forecast
10.6 Global Personalized Cancer Medicine Forecast by Method (2024-2029)
10.7 Global Personalized Cancer Medicine Forecast by Application (2024-2029)

11 Key Players Analysis
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Personalized Cancer Medicine Product Offered
11.1.3 AbbVie Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Personalized Cancer Medicine Product Offered
11.2.3 Johnson & Johnson Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Personalized Cancer Medicine Product Offered
11.3.3 Novartis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Information
11.4.2 Gilead Sciences Personalized Cancer Medicine Product Offered
11.4.3 Gilead Sciences Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Gilead Sciences Main Business Overview
11.4.5 Gilead Sciences Latest Developments
11.5 Roche
11.5.1 Roche Company Information
11.5.2 Roche Personalized Cancer Medicine Product Offered
11.5.3 Roche Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Roche Main Business Overview
11.5.5 Roche Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Personalized Cancer Medicine Product Offered
11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 Amgen
11.7.1 Amgen Company Information
11.7.2 Amgen Personalized Cancer Medicine Product Offered
11.7.3 Amgen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Amgen Main Business Overview
11.7.5 Amgen Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Personalized Cancer Medicine Product Offered
11.8.3 AstraZeneca Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Merck & Co
11.9.1 Merck & Co Company Information
11.9.2 Merck & Co Personalized Cancer Medicine Product Offered
11.9.3 Merck & Co Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Merck & Co Main Business Overview
11.9.5 Merck & Co Latest Developments
11.10 Takeda
11.10.1 Takeda Company Information
11.10.2 Takeda Personalized Cancer Medicine Product Offered
11.10.3 Takeda Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Takeda Main Business Overview
11.10.5 Takeda Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Personalized Cancer Medicine Product Offered
11.11.3 Merck KGaA Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Seagen
11.12.1 Seagen Company Information
11.12.2 Seagen Personalized Cancer Medicine Product Offered
11.12.3 Seagen Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Seagen Main Business Overview
11.12.5 Seagen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Personalized Cancer Medicine Product Offered
11.13.3 Eli Lilly Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Information
11.14.2 Ono Pharmaceutical Personalized Cancer Medicine Product Offered
11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Ono Pharmaceutical Main Business Overview
11.14.5 Ono Pharmaceutical Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Personalized Cancer Medicine Product Offered
11.15.3 Pfizer Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 GSK
11.16.1 GSK Company Information
11.16.2 GSK Personalized Cancer Medicine Product Offered
11.16.3 GSK Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 GSK Main Business Overview
11.16.5 GSK Latest Developments
11.17 Exelixis
11.17.1 Exelixis Company Information
11.17.2 Exelixis Personalized Cancer Medicine Product Offered
11.17.3 Exelixis Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Exelixis Main Business Overview
11.17.5 Exelixis Latest Developments
11.18 Regeneron
11.18.1 Regeneron Company Information
11.18.2 Regeneron Personalized Cancer Medicine Product Offered
11.18.3 Regeneron Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Regeneron Main Business Overview
11.18.5 Regeneron Latest Developments
11.19 Innovent
11.19.1 Innovent Company Information
11.19.2 Innovent Personalized Cancer Medicine Product Offered
11.19.3 Innovent Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Innovent Main Business Overview
11.19.5 Innovent Latest Developments
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Information
11.20.2 Hengrui Medicine Personalized Cancer Medicine Product Offered
11.20.3 Hengrui Medicine Personalized Cancer Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Hengrui Medicine Main Business Overview
11.20.5 Hengrui Medicine Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(cancer)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/06/25 10:26

160.56 円

172.79 円

206.47 円

ページTOPに戻る